PD 1 dependent interleukin 12 - Bonum Therapeutics
Alternative Names: PD1-IL-12Latest Information Update: 20 Jan 2023
At a glance
- Originator Bonum Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours